Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Indoco Remedies Parkinsons drug Rasagiline gets USFDA okay

      Indoco Remedies Parkinsons drug Rasagiline gets USFDA okay

      Medical Dialogues Bureau7 Oct 2019 1:23 PM IST
      New Delhi: Drugmaker, Indoco Remedies today received the US health regulator's final nod for Rasagiline 0.5 mg and 1 mg tablets for treating...
      Glenmark API facility in Baddi gets USFDA warning letter

      Glenmark API facility in Baddi gets USFDA warning letter

      Medical Dialogues Bureau7 Oct 2019 11:47 AM IST
      The Baddi facility is expected to contribute USD 30 million in total sales for this financial year which is about 7 per cent of the total US sales,...
      JnJ pledges USD 500 million investment to eliminate HIV, TB by 2030

      JnJ pledges USD 500 million investment to eliminate HIV, TB by 2030

      Medical Dialogues Bureau7 Oct 2019 9:30 AM IST
      NEW BRUNSWICK: Johnson & Johnson (JnJ) recently announced it has committed to ensuring more than $500 million is dedicated to world-class research...
      Bayer another US glyphosate trial delayed until further notice

      Bayer another US glyphosate trial delayed until further notice

      Medical Dialogues Bureau7 Oct 2019 9:00 AM IST
      "With the change in the trial schedule and no trial dates set through the rest of the year, the appeals of the three completed trials will be a...
      Lupin gets USFDA nod for generic equivalet of Dilantin

      Lupin gets USFDA nod for generic equivalet of Dilantin

      Medical Dialogues Bureau6 Oct 2019 10:00 AM IST
      Extended Phenytoin Sodium Capsules USP,100 mg (RLD: Dilantin) had annual sales of approximately USD 105 million in the U.S. (IQVIA MAT June 2019),...
      Novartis, Microsoft collaborate to transform medicine with AI

      Novartis, Microsoft collaborate to transform medicine with AI

      Medical Dialogues Bureau6 Oct 2019 9:45 AM IST
      The new lab aims to bolster Novartis AI capabilities from research through commercialization and help accelerate the discovery and development of...
      Q BioMed acquires USFDA approved cancer pain drug Strontium-89 Chloride

      Q BioMed acquires USFDA approved cancer pain drug Strontium-89 Chloride

      Medical Dialogues Bureau6 Oct 2019 9:15 AM IST
      Strontium-89 is an important therapeutic option for the treatment of metastatic bone cancer pain. The drug has a long history of providing...
      JnJ submits New Drug Application to USFDA for Spravato

      JnJ submits New Drug Application to USFDA for Spravato

      Medical Dialogues Bureau5 Oct 2019 9:00 AM IST
      New Delhi: The Janssen Pharmaceutical Companies of Johnson & Johnson(JnJ) recently announced the submission of a supplemental New Drug Application...
      Gilead Descovy wins USFDA approval for preventing sexually acquired HIV infection

      Gilead Descovy wins USFDA approval for preventing sexually acquired HIV infection

      Medical Dialogues Bureau4 Oct 2019 12:46 PM IST
      Descovy, a combination drug, was approved in 2016 to treat people already infected with HIV. It contains a newer formulation of a drug used in Gilead...
      Chennai-based Shield Healthcare acquires Brio Bliss Life Science, Nutri Synapzz

      Chennai-based Shield Healthcare acquires Brio Bliss Life Science, Nutri Synapzz

      Medical Dialogues Bureau4 Oct 2019 9:15 AM IST
      Shield Healthcare said pharmaceuticals and healthcare-focused private equity firm, Fulcrum Venture would also hold significant stake post the...
      Bristol-Myers CEO says Japan restrictive drug price policies risk diverting investment

      Bristol-Myers CEO says Japan restrictive drug price policies risk diverting investment

      Medical Dialogues Bureau4 Oct 2019 9:00 AM IST
      Japan is also a major centre for pharma research, producing drugs such as Opdivo, a blockbuster cancer drug licensed globally by Bristol-Myers.TOKYO:...
      Zydus announces positive results from EVIDENCES IV Phase 2 clinical trial of Saroglitazar Magnesium in NAFLD and NASH

      Zydus announces positive results from EVIDENCES IV Phase 2 clinical trial of Saroglitazar Magnesium in NAFLD and NASH

      Medical Dialogues Bureau3 Oct 2019 4:35 PM IST
      Zydus Cadila recently announced that Saroglitazar Magnesium has achieved the primary end-points in the EVIDENCES IV trial in patients with NAFLD and...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok